That's (phase 2) the preliminary efficacy bit mentioned. But it's not really looking for a great, high quality signal: just some evidence that some indicators

That's (phase 2) the preliminary efficacy bit mentioned. But it's not really looking for a great, high quality signal: just some evidence that some indicators move in patients and not necessarily even statistical significance before moving to a phase 3 trial designed to measure benefit. They expect a big enough effect on the virus to be able to measure it in this tiny population.